Literature DB >> 18442195

Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2.

Bo Zhang1, Chang-Liang Wang, Wen-Hua Zhao, Ming Lv, Chun-Ying Wang, Wei-Xia Zhong, Wu-Yuan Zhou, Wen-Sheng Yu, Yan Zhang, Sheng Li.   

Abstract

AIM: To study the effect of 5-lipoxygenase/cyclooxygenase-2 (5-LOX/COX-2) dual inhibitor 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) on proliferation and apoptosis of the pancreatic cancer cell line Capan-2 and the effect of DHDMBF30 on human pancreatic cancer in a nude mouse model.
METHODS: Investigate the effect of 5-LOX/COX-2 dual inhibitor DHDMBF30 on proliferation and apoptosis of the pancreatic cancer cell line Capan-2 by RT-PCR, MTT assay, FCM and electron microscope. Cell line Capan-2 was inoculated percutaneously on the outer thigh of 12 nude mice. The VEGF mRNA of transplantation tumor was detected by RT-PCR.
RESULTS: DHDMBF30 inhibits the proliferation of cell line Capan2, reduces the expression of 5-LOX, COX-2 and VEGF. After Capan2 was treated with DHDMBF30, we found that the apoptosis peak of the experimental group was significantly higher than that of the contrast group (3.08 +/- 1.89 vs 27.67 +/- 0.52, P < 0.001). The tumor weight of the DHDMBF30 group was significantly lower than PBS control groups (1.35 +/- 0.47 vs 2.92 +/- 0.73, P < 0.01). Expression of VEGF in the DHDMBF30 group was significantly decreased.
CONCLUSION: DHDMBF30 inhibits the proliferation of the pancreatic cell line Capan2, and induces apoptosis and inhibits the growth of pancreatic cancer in nude mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442195      PMCID: PMC2708359          DOI: 10.3748/wjg.14.2494

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin.

Authors:  Stefano Fiorucci; Eleonora Distrutti; Octavio Menezes de Lima; Mario Romano; Andrea Mencarelli; Miriam Barbanti; Ernesto Palazzini; Antonio Morelli; John L Wallace
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

2.  Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma.

Authors:  R Ohno; K Yoshinaga; T Fujita; K Hasegawa; H Iseki; H Tsunozaki; W Ichikawa; Z Nihei; K Sugihara
Journal:  Cancer       Date:  2001-05-15       Impact factor: 6.860

Review 3.  Leukotriene synthesis by epithelial cells.

Authors:  M Luo; S Lee; T G Brock
Journal:  Histol Histopathol       Date:  2003-04       Impact factor: 2.303

4.  New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position.

Authors:  J M Janusz; P A Young; J M Ridgeway; M W Scherz; K Enzweiler; L I Wu; L Gan; J Chen; D E Kellstein; S A Green; J L Tulich; T Rosario-Jansen; I J Magrisso; K R Wehmeyer; D L Kuhlenbeck; T H Eichhold; R L Dobson
Journal:  J Med Chem       Date:  1998-08-27       Impact factor: 7.446

Review 5.  Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer.

Authors:  X Z Ding; W G Tong; T E Adrian
Journal:  Pancreatology       Date:  2001       Impact factor: 3.996

6.  The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma.

Authors:  Huiying Zhi; Jian Zhang; Gengxi Hu; Jiayun Lu; Xiuqin Wang; Chuannong Zhou; Min Wu; Zhihua Liu
Journal:  Int J Cancer       Date:  2003-09-01       Impact factor: 7.396

Review 7.  Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

Authors:  J Martel-Pelletier; D Lajeunesse; P Reboul; J-P Pelletier
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 8.  Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.

Authors:  Giovanni de Gaetano; Maria Benedetta Donati; Chiara Cerletti
Journal:  Trends Pharmacol Sci       Date:  2003-05       Impact factor: 14.819

9.  Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.

Authors:  Claudia P Schroeder; Peiying Yang; Robert A Newman; Reuben Lotan
Journal:  J Exp Ther Oncol       Date:  2007

10.  Inhibitory activity of tryptanthrin on prostaglandin and leukotriene synthesis.

Authors:  Henning Danz; Stefka Stoyanova; Olivier A R Thomet; Hans-Uwe Simon; Gerd Dannhardt; Holger Ulbrich; Matthias Hamburger
Journal:  Planta Med       Date:  2002-10       Impact factor: 3.352

View more
  4 in total

Review 1.  Cyclooxygenases and lipoxygenases in cancer.

Authors:  Claus Schneider; Ambra Pozzi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.

Authors:  Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Jagan M R Patlolla; Laura Biddick; Stan Lightfoot; Xue-Ru Wu; Vernon Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-02

3.  Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.

Authors:  Suniti Misra; Shibnath Ghatak; Neha Patil; Prasad Dandawate; Vinita Ambike; Shreelekha Adsule; Deepak Unni; K Venkateswara Swamy; Subhash Padhye
Journal:  Bioorg Med Chem       Date:  2013-02-27       Impact factor: 3.641

4.  Anti-Inflammatory, Anticholinesterase, and Antioxidant Potential of Scopoletin Isolated from Canarium patentinervium Miq. (Burseraceae Kunth).

Authors:  R Mogana; K Teng-Jin; C Wiart
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-25       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.